{"product_id":"nkf-pharma-pestle-analysis","title":"Nanjing King-Friend Biochemical Pharmaceutical PESTLE Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePlan Smarter. Present Sharper. Compete Stronger.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eDiscover how political shifts, economic pressures, social trends, technological advances, legal changes, and environmental risks are shaping Nanjing King‑Friend Biochemical Pharmaceutical’s strategic outlook in our concise PESTLE summary; these external forces reveal hidden risks and growth levers for investors and strategists. Interested in actionable recommendations and data-driven forecasts? Purchase the full PESTLE analysis now for the complete, ready-to-use report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eolitical factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eChina healthcare policy and VBP\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eChinas national volume-based procurement and hospital tendering have compressed prices while expanding volumes, with authorities reporting over 100 billion yuan saved by VBP through 2020. King-Friend faces margin pressure in LMWH and heparin and must pursue scale to preserve revenue. Recent policy pushes on generics quality consistency and GMP favor compliant producers. Close engagement with NHSA, provincial health bureaus and hospital alliances is vital to retain listings.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory alignment and approvals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRegulatory alignment via NMPA approval pathways and potential FDA\/EMA filings critically shape King-Friend’s market access; China joined ICH in 2017, pushing harmonized pharmacopeial specs for heparin potency and impurity limits. After the 2008 heparin contamination, inspection intensity increased, and with China supplying about 60% of global porcine heparin, rapid compliance preserves export eligibility.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeopolitics and trade barriers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eUS–China and EU–China tensions can trigger tariffs, import alerts or extra inspections on APIs and injectables, increasing lead times and costs; industry estimates in 2024 put China’s share of global generic API exports at roughly 40%. Diversifying export destinations and forming local partnerships reduces country risk and revenue concentration. Government export facilitation or restrictions on medical products can rapidly alter supply–demand and pricing dynamics. Proactive compliance, batch-level traceability and transparent QMS reduce border scrutiny and delisting risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIndustrial policy and incentives\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eChina's industrial policy (14th Five-Year Plan follow-ups through 2024) prioritizes biopharma upgrading, with a 75% R\u0026amp;D super-deduction for qualifying firms and targeted tax\/incentive packages in national high-end manufacturing zones, enabling grants and subsidies that can lower bioprocess or quality-lab capex and speed automation; overseas localization rules also drive fill-finish JV opportunities and procurement\/financing advantages when aligned with policy.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e75% R\u0026amp;D super-deduction\u003c\/li\u003e\n\u003cli\u003eTargeted zone incentives lowering capex\u003c\/li\u003e\n\u003cli\u003eGrants for automation\/quality labs\u003c\/li\u003e\n\u003cli\u003eLocalization drives overseas JVs and procurement edge\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePublic health preparedness\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEpidemic responses and stockpiling policies drive spikes in anticoagulant demand in critical care; WHO reported 90% of countries experienced health-service disruptions in 2020. China’s National Centralized Drug Procurement pilot (4+7) achieved ~52% average price reductions, showing central purchasing can reallocate volumes rapidly. Political prioritization of supply security favors vertically integrated chains and maintaining surge capacity strengthens government procurement relationships.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eWHO 2020: 90% countries reported disruptions\u003c\/li\u003e\n\u003cli\u003e4+7 pilot: ~52% avg price reduction\u003c\/li\u003e\n\u003cli\u003eCentral purchasing: rapid volume reallocation (weeks)\u003c\/li\u003e\n\u003cli\u003eSurge capacity: improves govt contract prospects\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVBP\/4+7 slashes prices, squeezing LMWH margins; China supplies \u003cstrong\u003e60%\u003c\/strong\u003e heparin\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVolume-based procurement and hospital tendering cut prices (VBP saved \u0026gt;100bn yuan through 2020; 4+7 pilot ~52% avg price drop), squeezing LMWH\/heparin margins and forcing scale. China supplies ~60% of global porcine heparin and ~40% of generic API exports (2024), raising export risk amid US\/EU tensions. 75% R\u0026amp;D super-deduction and zone incentives lower capex and favor compliant, vertically integrated producers.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFactor\u003c\/th\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eImpact\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eVBP\/4+7\u003c\/td\u003e\n\u003ctd\u003eSaved \u0026gt;100bn CNY; ~52% price cut\u003c\/td\u003e\n\u003ctd\u003eMargin pressure\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSupply concentration\u003c\/td\u003e\n\u003ctd\u003e~60% heparin; ~40% API exports (2024)\u003c\/td\u003e\n\u003ctd\u003eExport scrutiny risk\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIncentives\u003c\/td\u003e\n\u003ctd\u003e75% R\u0026amp;D super-deduction\u003c\/td\u003e\n\u003ctd\u003eLowered capex\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eExplores how external macro-environmental factors across Political, Economic, Social, Technological, Environmental and Legal dimensions uniquely affect Nanjing King‑Friend Biochemical Pharmaceutical, providing data-backed, region-specific insights and forward-looking implications to support executives, investors and strategic planning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA clean, summarized PESTLE of Nanjing King‑Friend Biochemical Pharmaceutical that relieves briefing pain points by clearly segmenting political, economic, social, technological, legal and environmental risks for quick presentation and decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eE\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003economic factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal demand for anticoagulants\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAging populations (UN: global 65+ share rising from ~9% in 2020 to ~16% by 2050) and higher cardiovascular incidence sustain steady LMWH\/heparin demand, while elective surgeries and ICU utilization drive cyclical VTE prophylaxis volumes. DOACs now account for over 60% of oral anticoagulant prescriptions in many high‑income markets, reshaping product mix but hospital LMWH use remains robust. Channel-level forecasting lowers inventory and stockout risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRaw material cost volatility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePorcine mucosa supply in China is highly cyclical; African swine fever reduced the national pig herd by about 40% in 2018–19, causing acute raw-material tightness. Input-price spikes can compress margins unless sales contracts include pass-through clauses. Vertical integration and multi-region sourcing materially stabilize COGS, while strategic stockpiles provide short-term cushioning against supply shocks.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCurrency and financing conditions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNanjing King-Friend’s export exposure makes revenues sensitive to RMB–USD\/EUR moves after RMB traded roughly 6.8–7.4 per USD in 2024–25, translating FX swings directly into top-line volatility. Hedging policies and operational natural offsets (domestic sourcing, EUR invoicing) can protect EBITDA against currency-driven margin erosion. Interest rate trends — China 1Y LPR 3.45% and 5Y 4.20%, US fed funds ~5.25–5.50% in 2024–25 — affect working capital costs and capex timing. Strong compliance and ESG disclosure improve access to credit and ESG-linked financing. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePricing pressure and competition\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eGenericized markets invite intense price competition from domestic and international players; China’s centralized procurement has driven price cuts often exceeding 50% for selected generics, pressuring margins. Differentiation via proven quality, supply reliability and after-sales service wins hospital tenders. Scale in purification and fill-finish lowers unit costs, while customer concentration risk makes geographic diversification essential.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePrice cuts: centralized procurement \u0026gt;50%\u003c\/li\u003e\n\u003cli\u003eDifferentiation: quality, reliability, service\u003c\/li\u003e\n\u003cli\u003eScale: lower unit COGS via purification\/fill-finish\u003c\/li\u003e\n\u003cli\u003eRisk: customer concentration → diversify geographies\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLogistics and supply chain costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eCold-chain and sterile distribution raise logistics premiums (roughly 20–35% higher transport and handling), making Nanjing King-Friend highly fuel and freight sensitive; port congestion and volatile container rates (spot ranges broadly from about 1,200–3,500 USD\/FEU across 2022–24) can disrupt export schedules and inventory turns. Nearshoring and regional warehousing cut lead times from weeks to days and lower expediting costs, while digital demand planning tied to hospital schedules can reduce stockouts and excess safety stock by ~20–30%.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ecold-chain premium: 20–35%\u003c\/li\u003e\n\u003cli\u003econtainer rate range (2022–24): 1,200–3,500 USD\/FEU\u003c\/li\u003e\n\u003cli\u003elead-time cut via nearshoring: weeks to days\u003c\/li\u003e\n\u003cli\u003edemand-planning impact: ~20–30% fewer stockouts\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVBP\/4+7 slashes prices, squeezing LMWH margins; China supplies \u003cstrong\u003e60%\u003c\/strong\u003e heparin\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAging 65+ rising (UN: ~9% in 2020 → ~16% by 2050) sustains anticoagulant demand; DOACs \u0026gt;60% in many high‑income markets, but hospital LMWH use stays strong. RMB 6.8–7.4\/USD (2024–25) and interest rates (China 1Y LPR 3.45%) drive FX\/working‑capital risk. Cold‑chain adds 20–35% logistics premium; container spot 1,200–3,500 USD\/FEU affects export costs and inventory.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003eImpact\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAging 65+\u003c\/td\u003e\n\u003ctd\u003e9%→16% (2020→2050)\u003c\/td\u003e\n\u003ctd\u003e↑ Baseline demand\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDOAC share\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;60%\u003c\/td\u003e\n\u003ctd\u003eProduct mix shift\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRMB\/USD\u003c\/td\u003e\n\u003ctd\u003e6.8–7.4 (2024–25)\u003c\/td\u003e\n\u003ctd\u003eRevenue volatility\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCold‑chain premium\u003c\/td\u003e\n\u003ctd\u003e20–35%\u003c\/td\u003e\n\u003ctd\u003eHigher COGS\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eContainer rates\u003c\/td\u003e\n\u003ctd\u003e1,200–3,500 USD\/FEU\u003c\/td\u003e\n\u003ctd\u003eExport cost swings\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eNanjing King-Friend Biochemical Pharmaceutical PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact Nanjing King-Friend Biochemical Pharmaceutical PESTLE Analysis document you’ll receive after purchase—fully formatted and ready to use. The layout, content, and structure visible are identical to the downloadable file. No placeholders or teasers; this is the final, professionally structured report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"PortersFiveForce","offers":[{"title":"Default Title","offer_id":55675487650169,"sku":"nkf-pharma-pestle-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0914\/5276\/8633\/files\/nkf-pharma-pestle-analysis.png?v=1755809812","url":"https:\/\/portersfiveforce.com\/products\/nkf-pharma-pestle-analysis","provider":"Porter's Five Forces","version":"1.0","type":"link"}